Rifaximin 550 MG
Sponsors
University of Michigan, Bonderup, Ole K., M.D., Taipei Medical University Shuang Ho Hospital, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bahria University
Conditions
Acute Radiation EnteritisBladder (Urothelial, Transitional Cell) CancerCervical AdenocarcinomaChronic Liver DiseaseCollagenous ColitisDecompensated CirrhosisDiarrhea TravelersDiarrhoea;Acute
Phase 1
Modulation of Gut Microbiota by Rifaximin in PD Patients
NCT03958708
Start: 2019-05-13End: 2020-12-01Target: 20Updated: 2019-05-22
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Not yet recruitingNCT06783153
Start: 2025-01-20End: 2025-12-31Target: 80Updated: 2025-01-20
Phase 3
Phase 4
A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
CompletedNCT03219528
Start: 2018-02-13End: 2024-02-28Updated: 2025-04-27
Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct
RecruitingNCT05677282
Start: 2022-10-28End: 2025-12-31Target: 150Updated: 2025-05-31
To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
CompletedNCT05867550
Start: 2023-01-03End: 2023-06-10Updated: 2023-07-27
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
RecruitingNCT06538077
Start: 2025-02-01End: 2027-08-31Target: 336Updated: 2025-06-10